Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
NCT05669833 · View on ClinicalTrials.gov ↗
Study Summary
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Conditions Studied
Interventions
- DRUG Guselkumab
- DRUG Golimumab
Study Locations (14)
Florida
- Family Arthritis Center — Loxahatchee Groves
- Healing Rheumatology — Plant City
- Southwest Florida Rheumatology — Riverview
Ohio
- Cincy Arthritis — Blue Ash
- Southern Ohio Rheumatology — Wheelersburg
Texas
- Heritage Rheumatology and Arthritis Care — Colleyville
- Texas Arthritis Center — El Paso
Georgia
- Parris and Associates — Lilburn
Massachusetts
- University of Massachusetts Chan Medical School — Worcester
Nebraska
- University of Nebraska Medical Center — Omaha
New York
- New York University — New York
Pennsylvania
- Hospital at the University of Pennsylvania — Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-07-14 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05669833
The ClinicalTrials.gov registry entry for NCT05669833 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,457 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions — of which Guselkumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05669833 reports 14 study locations spanning 10 distinct geographic areas — top geographies include Florida, Ohio, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05669833 about?
NCT05669833 is a clinical study titled "Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients". The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
What is the current status of trial NCT05669833?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2023-07-14. Estimated completion is 2026-10.
What conditions does trial NCT05669833 study?
This clinical trial studies the following conditions: Psoriatic Arthritis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05669833?
The interventions under investigation include: Guselkumab (DRUG), Golimumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05669833?
This trial is sponsored by University of Pennsylvania, which has 1,457 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05669833 being conducted?
This trial has 14 study locations across Florida, Georgia, Massachusetts, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.